November 29, 2016 - By Louis Casey
In a a report released on Tuesday, 29 November, stock analysts at Barclays’s equities division cut United Therapeutics Corporation (NASDAQ:UTHR)‘s stock rating from a”Equal-Weight” to “Underweight”.
Out of 6 analysts covering United Therapeutics (NASDAQ:UTHR), 2 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 33% are positive. $244 is the highest target while $95 is the lowest. The $174 average target is 36.32% above today’s ($127.64) stock price. United Therapeutics has been the topic of 9 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Friday, October 28 by Ladenburg Thalmann. The stock of United Therapeutics Corporation (NASDAQ:UTHR) earned “Equal-Weight” rating by Barclays Capital on Friday, February 26. The stock of United Therapeutics Corporation (NASDAQ:UTHR) earned “Sector Perform” rating by RBC Capital Markets on Wednesday, July 29. The company was maintained on Friday, July 31 by Argus Research. H.C. Wainwright downgraded the stock to “Neutral” rating in Wednesday, June 15 report. The firm has “Outperform” rating given on Monday, August 17 by Cowen & Co. Ladenburg Thalmann downgraded United Therapeutics Corporation (NASDAQ:UTHR) on Friday, April 29 to “Neutral” rating. Argus Research downgraded the stock to “Hold” rating in Tuesday, May 24 report.
About 326,173 shares traded hands. United Therapeutics Corporation (NASDAQ:UTHR) has risen 13.02% since April 26, 2016 and is uptrending. It has outperformed by 7.76% the S&P500.
Analysts await United Therapeutics Corporation (NASDAQ:UTHR) to report earnings on February, 23. They expect $3.56 EPS, up 61.09% or $1.35 from last year’s $2.21 per share. UTHR’s profit will be $149.00 million for 8.96 P/E if the $3.56 EPS becomes a reality. After $3.63 actual EPS reported by United Therapeutics Corporation for the previous quarter, Wall Street now forecasts -1.93% negative EPS growth.
Insitutional Activity: The institutional sentiment decreased to 0.89 in Q2 2016. Its down 0.11, from 1 in 2016Q1. The ratio is negative, as 52 funds sold all United Therapeutics Corporation shares owned while 121 reduced positions. 39 funds bought stakes while 134 increased positions. They now own 47.41 million shares or 3.79% less from 49.28 million shares in 2016Q1.
Hancock Company has 5,493 shares for 0.02% of their US portfolio. Ncm Cap Advisers Incorporated, a North Carolina-based fund reported 1,832 shares. Independent Portfolio Consultants holds 175 shares or 0.01% of its portfolio. Barclays Plc last reported 12,618 shares in the company. Ubs Asset Mgmt Americas accumulated 0.03% or 246,563 shares. Da Davidson has 0% invested in the company for 868 shares. Proshare Advisors Ltd Liability Com accumulated 0.05% or 38,379 shares. Cwm Limited accumulated 0% or 50 shares. Goldman Sachs Group Inc holds 1.05M shares or 0.04% of its portfolio. Nuveen Asset Mgmt Ltd Llc holds 0.03% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR) for 49,847 shares. Canada Pension Plan Invest Board holds 44,102 shares or 0.02% of its portfolio. Grt Capital Prtn Ltd Com reported 3,317 shares or 0.09% of all its holdings. Meeder Asset Mngmt Inc holds 17 shares or 0% of its portfolio. American Intll Group Inc has 0% invested in the company for 86,324 shares. Regentatlantic Capital Limited Liability Corp has invested 0.14% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR).
Insider Transactions: Since June 2, 2016, the stock had 0 insider buys, and 27 sales for $5.64 million net activity. ROTHBLATT MARTINE A also sold $149,736 worth of United Therapeutics Corporation (NASDAQ:UTHR) shares. Another trade for 2,000 shares valued at $231,247 was sold by Thompson Tommy G. PATUSKY CHRISTOPHER sold 5,000 shares worth $657,123. On Thursday, June 2 DWEK RAYMOND sold $356,448 worth of the stock or 3,000 shares.
United Therapeutics Corporation is a biotechnology company. The company has a market cap of $5.34 billion. The Firm is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. It has a 8.6 P/E ratio. The Company’s therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 Inhibitor and Monoclonal Antibody (MAb).
According to Zacks Investment Research, “UTD THERAPEUTIC is a biotechnology company focused on combating cardiovascular, inflammatory, and infectious diseases with unique therapeutic products. These products include pharmaceuticals, arginine products and telemedicine services.”
United Therapeutics Corporation, incorporated on June 26, 1996, is a biotechnology company. The Firm is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company’s therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb). The Firm is engaged in early-stage research and development into a range of organ transplantation-related technologies. It is also engaged in a range of research and development activities in xenotransplantation, regenerative medicine and ex-vivo lung perfusion, all of which are intended to supply transplantable organs and tissues. These activities are focused on lungs, but are also being applied to other organs, such as hearts and kidneys.
More notable recent United Therapeutics Corporation (NASDAQ:UTHR) news were published by: Fool.com which released: “Better Buy: Organovo Holdings, Inc. vs. United Therapeutics Corporation” on October 14, 2016, also Prnewswire.com with their article: “SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating United …” published on October 31, 2016, Prnewswire.com published: “United Therapeutics Corporation Announces Executive Leadership Changes” on April 28, 2016. More interesting news about United Therapeutics Corporation (NASDAQ:UTHR) were released by: Prnewswire.com and their article: “United Therapeutics Corporation To Present At The 2016 Wedbush PacGrow …” published on August 10, 2016 as well as Prnewswire.com‘s news article titled: “United Therapeutics Corporation Reports Second Quarter 2016 Financial Results” with publication date: July 28, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey